{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Proto Labs, Inc.
Is Proto Labs, Inc. overvalued or undervalued?
As of November 28, 2025, Proto Labs, Inc. is fairly valued with a P/E ratio of 44, having outperformed the S&P 500 over the past year with a 24.56% return, but its 5-year return of -63.37% indicates a challenging long-term outlook.
Is Proto Labs, Inc. overvalued or undervalued?
As of November 21, 2025, Proto Labs, Inc. is considered very expensive and overvalued, with a high P/E ratio of 44 and a PEG ratio of 4.96, significantly outpacing its peers and showing a concerning long-term performance decline despite a strong year-to-date return.
Is Proto Labs, Inc. overvalued or undervalued?
As of November 7, 2025, Proto Labs, Inc. is considered very expensive with a P/E ratio of 44 and overvaluation compared to peers, despite strong year-to-date returns of 25.43%, but its long-term performance has been poor, raising concerns about the sustainability of its high valuation.
Is Proto Labs, Inc. overvalued or undervalued?
As of November 7, 2025, Proto Labs, Inc. is considered overvalued with a valuation grade of "very expensive," reflected in its high P/E ratio of 44 and a significant decline of 62.60% over the past five years, despite a strong year-to-date return of 25.33%.
Is Proto Labs, Inc. technically bullish or bearish?
As of October 31, 2025, Proto Labs, Inc. shows a mildly bullish trend with mixed technical signals, having outperformed the S&P 500 year-to-date and over the past year, but underperformed over the longer 3- and 5-year periods.
Is Proto Labs, Inc. technically bullish or bearish?
As of October 31, 2025, Proto Labs, Inc. has a mildly bullish technical trend, supported by bullish MACD and KST indicators, despite mixed signals from Dow Theory and a neutral RSI.
Proto Labs, Inc. Experiences Valuation Adjustment Amid Strong Yearly Performance Metrics
Proto Labs, Inc. has recently adjusted its valuation, with its current price at $49.76. Over the past year, the company has achieved an impressive return of 81.61%. Key financial metrics include a P/E ratio of 44 and a return on equity of 3.12%, indicating its operational efficiency within the specialty chemicals sector.
Is Proto Labs, Inc. technically bullish or bearish?
As of October 31, 2025, Proto Labs, Inc. shows a mildly bullish trend with positive MACD and KST indicators, but mixed signals from Dow Theory suggest caution despite strong year-to-date and annual performance compared to the S&P 500.
Is Proto Labs, Inc. technically bullish or bearish?
As of October 31, 2025, Proto Labs, Inc. exhibits a mildly bullish technical trend, supported by bullish MACD and KST indicators, despite mixed signals from Dow Theory, while outperforming the S&P 500 year-to-date and over the past year.
Proto Labs Adjusts Valuation Grade Amidst Strong Yearly Performance and Investor Confidence
Proto Labs, Inc. has recently experienced a change in its valuation grade, moving to a fair classification. Key financial metrics include a P/E ratio of 44 and a Price to Book Value of 1.39. The company has shown a significant return over the past year, outperforming the S&P 500.
Is Proto Labs, Inc. overvalued or undervalued?
As of October 24, 2025, Proto Labs, Inc. is fairly valued with a P/E ratio of 44, strong recent performance with a 1-year stock return of 103.65%, but a volatile history reflected in a 5-year return of -60.19% compared to the S&P 500's 95.99%.
Proto Labs, Inc. Experiences Valuation Adjustment Amid Strong Performance Metrics
Proto Labs, Inc. has recently adjusted its valuation, with its stock price at $54.64. Over the past year, the company has achieved a 103.65% return, significantly surpassing the S&P 500. Key financial metrics include a P/E ratio of 44 and a return on equity of 3.12%.
Is Proto Labs, Inc. overvalued or undervalued?
As of October 24, 2025, Proto Labs, Inc. is fairly valued with a P/E ratio of 44, outperforming the S&P 500 with a 103.65% return over the past year, while its valuation metrics compare favorably against peers like Genesis Energy LP and Ecovyst, Inc.
Is Proto Labs, Inc. overvalued or undervalued?
As of October 24, 2025, Proto Labs, Inc. is fairly valued with a P/E ratio of 44, an EV to EBITDA of 13.93, and a Price to Book Value of 1.39, having outperformed the S&P 500 with a 1-year return of 103.65% despite a challenging 5-year return of -60.19%.
Proto Labs, Inc. Experiences Valuation Adjustment Amid Strong Yearly Stock Performance
Proto Labs, Inc., a small-cap in the specialty chemicals sector, has adjusted its valuation, with its stock currently priced at $52.16. Over the past year, it achieved a 78.81% return, significantly exceeding the S&P 500's performance. Key metrics include a P/E ratio of 44 and a ROCE of 4.13%.
Proto Labs, Inc. Hits New 52-Week High of $55.28
Proto Labs, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low and demonstrating strong annual performance. With a market capitalization of USD 1,200 million, the company shows effective financial management, highlighted by its P/E and price-to-book ratios, and a focus on reinvestment.
Proto Labs, Inc. Hits New 52-Week High of $52.16
Proto Labs, Inc. has achieved a new 52-week high, reflecting a significant performance improvement over the past year. With a market capitalization of USD 1,200 million, a P/E ratio of 44.00, and a negative debt-to-equity ratio, the company demonstrates a strong financial position and operational effectiveness in the specialty chemicals sector.
Proto Labs Faces Mixed Signals Amid Valuation Adjustments and Market Trends
Proto Labs, Inc. has recently experienced a change in its evaluation, influenced by shifts in financial metrics and market position. The company's technical indicators show a transition in trend, while its valuation has moved to a classification of very expensive, reflecting its premium standing in the specialty chemicals industry.
Proto Labs, Inc. Experiences Revision in Stock Evaluation Amid Market Fluctuations
Proto Labs, Inc., a small-cap specialty chemicals company, has adjusted its valuation metrics, showing a P/E ratio of 44 and a price to book value of 1.39. While it has outperformed the S&P 500 year-to-date, its long-term performance has lagged behind the broader market.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
